They also demonstrate that in a melanoma-bearing mouse model combination treatment of anti-CD36 antibody combined with anti-PD-1 shows a stronger capability to restrict cancer growth compared with either anti-CD36 or anti-PD-1 alone [133]. This evidence concerns the gene CD36 and melanoma.